Loading...

TLPH TALPHERA INC US FDA Inspections 8-K Filing

TLPH

TLPH

TALPHERA INC

(TLPH)

2023 8-K

Show Summary

Show Summary

Failure to Meet Listing Sta...

Financial Statements

Securities Sale

Financial Results

Nasdaq Compliance Notice

Financial Results

Agreement Amendment

Management Change

Departure of Directors and ...

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results Announcement

Departure of Directors and ...

Private Placement

Agreement with XOMA for Pur...

Financial Results Announcement

Annual Meeting of Stockholders

Change in Registrant's Cert...

FDA Declines Emergency Use ...

Earnings Reports

Equity Offerings

Compliance with Nasdaq Mini...

Financial Results Announcement

Sale of DSUVIA and Loan Rep...

Financial Results and Resta...

Asset Purchase Agreement

External Links:

ACELRX PHARMACEUTICALS INC submitted a request for Emergency Use Authorization for Niyad, but the FDA declined to issue the EUA at this time. The company plans to initiate a registrational study of Niyad and submit a Pre-Market Application in 2024.

AI Assistant

TALPHERA INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.